Concomitant administration of BILR 355/r with emtricitabine/tenofovir disoproxil fumarate increases exposure to emtricitabine and tenofovir: a randomized, open-label, prospective study. [electronic resource]
Producer: 20110609Description: 163-70 p. digitalISSN:- 1742-7843
- Adenine -- administration & dosage
- Adult
- Anti-HIV Agents -- administration & dosage
- Antiretroviral Therapy, Highly Active -- adverse effects
- Azepines -- adverse effects
- Cross-Over Studies
- Deoxycytidine -- administration & dosage
- Drug Interactions
- Emtricitabine
- Female
- HIV Protease Inhibitors -- administration & dosage
- Half-Life
- Humans
- Male
- Metabolic Clearance Rate
- Middle Aged
- Organophosphonates -- administration & dosage
- Pyridines -- adverse effects
- Reproducibility of Results
- Reverse Transcriptase Inhibitors -- administration & dosage
- Ritonavir -- administration & dosage
- Tenofovir
- Young Adult
No physical items for this record
Publication Type: Clinical Trial; Clinical Trial, Phase I; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.